» Articles » PMID: 33921760

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them

Abstract

Gastric cancer (GC) is the third cause of cancer-related death worldwide; the prognosis is poor especially in the case of metastatic disease. Liver, lymph nodes, peritoneum, and lung are the most frequent sites of metastases from GC; however, bone metastases from GC have been reported in the literature. Nevertheless, it is unclear how the metastatic sites may affect the prognosis. In particular, knowledge about the impact of bone metastases on GC patients' outcome is scant, and this may be related to the rarity of bone lesions and/or their underestimation at the time of diagnosis. In fact, there is still a lack of specific recommendation for their detection at the diagnosis. Then, the majority of the evidences in this field came from retrospective analysis on very heterogeneous study populations. In this context, the aim of this narrative review is to delineate an overview about the evidences existing about bone metastases in GC patients, focusing on their incidence and biology, the prognostic role of bone involvement, and their possible implication in the treatment choice.

Citing Articles

Heterogeneity and prognosis of single organ metastases in gastric cancer.

Zhao Q, Quan Z, Liu S, Wang Y, Guo H Transl Gastroenterol Hepatol. 2024; 9:61.

PMID: 39503034 PMC: 11535815. DOI: 10.21037/tgh-24-11.


A Rare Case of Early Gastric Cancer With Rapid Bone Involvement.

Ashikian T, Babaian M Cureus. 2024; 16(8):e66317.

PMID: 39108763 PMC: 11302998. DOI: 10.7759/cureus.66317.


Diffuse type gastric adenocarcinoma with atypical presentation: A case report.

Edwin G, Mbishi Y, Zerd F, Komanya F, Alphonce B, Sindato E Clin Case Rep. 2024; 12(5):e8849.

PMID: 38721558 PMC: 11077255. DOI: 10.1002/ccr3.8849.


Epidemiological and pathological characteristics of spinal metastases from gastrointestinal cancers - a series of 40 cases.

Selaru S, Sava A, Scripcariu D, Costea C, Dumitrescu A, Costachescu B Rom J Morphol Embryol. 2023; 64(2):225-234.

PMID: 37518880 PMC: 10520379. DOI: 10.47162/RJME.64.2.13.


Gastric Cancer With Multiple Bone Metastases: An Uncommon Primary Presentation.

Barbosa-Martins J, Marques S, Miranda O, Lima B, Cotter J Cureus. 2022; 14(9):e29467.

PMID: 36299933 PMC: 9587900. DOI: 10.7759/cureus.29467.


References
1.
Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

2.
Pollen J, Witztum K, Ashburn W . The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984; 142(4):773-6. DOI: 10.2214/ajr.142.4.773. View

3.
Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

4.
Van Cutsem E, Bang Y, Mansoor W, Petty R, Chao Y, Cunningham D . A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017; 28(6):1316-1324. DOI: 10.1093/annonc/mdx107. View

5.
Gurzu S, Jung I, Kadar Z . Aberrant metastatic behavior and particular features of early gastric cancer. APMIS. 2015; 123(12):999-1006. DOI: 10.1111/apm.12469. View